On May 30, 2025, Zymeworks Inc. announced that its drug zanidatamab received conditional approval from China's NMPA for treating certain cancer patients, pending further clinical validations; the company has received $61 million so far and could earn up to $20 million more for this approval, along with tiered royalties up to 20% on future sales.